



## Living Cell Technologies Limited

**ACN:** 104 028 042

**ASX:** LCT

**OTCQB:** LVCLY

### ASX ANNOUNCEMENT

## Board Changes

---

**Sydney, Australia & Auckland, New Zealand – 31 October 2022** – Living Cell Technologies (ASX: LCT; OTCQB: LVCLY) announces the resignations of Professor Bernie Tuch, Mr Robert Willcocks and Dr Andrew Kelly as directors of the Company and the appointment of Mr David Hainsworth and Mr Bradley Dilkes to the Board. Professor Carolyn Sue will continue as a director.

The three outgoing directors decided to resign in advance of resolutions for their removal being put to the Company's Annual General meeting on 10 November 2022 when it appeared that such resolutions would pass. It was felt that doing so would enable the orderly and efficient transition to the new directorships.

Professor Bernie Tuch will continue in his role as interim CEO until the end of January 2023.

Contact at the company:

Mr Bradley Dilkes

[brad@alignmentcapital.com.au](mailto:brad@alignmentcapital.com.au)

Authorised for release by the Board of Living Cell Technologies Limited.

– Ends –

**For further information:** [www.lctglobal.com](http://www.lctglobal.com)

<p><b>At the Company:</b> Bradley Dilkes Associate Director Mobile: +61 422 180 317 <a href="mailto:brad@alignmentcapital.com.au">brad@alignmentcapital.com.au</a></p>	<p><b>For media queries:</b> Anthony Fensom Republic PR Mobile: +61 407 112 623 <a href="mailto:anthony@republicpr.com.au">anthony@republicpr.com.au</a></p>
--	--

## **About NTCELL**

NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells that are sourced from a unique herd of designated pathogen-free pigs bred from stock originally discovered in the remote sub-Antarctic Auckland Islands. Choroid plexus cells are naturally occurring 'support' cells for the brain and secrete cerebrospinal fluid (CSF), which contains a range of factors that support nerve cell functions and protective enzymes that are crucial for nerve growth and healthy functioning. In NTCELL, the porcine choroid plexus cells are coated with alginate to protect them from attack by the immune system. Therefore, no immunosuppressive regimen needs to be administered to recipients.

## **About Living Cell Technologies**

Living Cell Technologies Limited (ASX:LCT) is an Australasian biotechnology company that is focused on discovering and developing novel treatments for debilitating conditions such as diabetes and Parkinson's disease.

LCT is listed on the Australian (ASX:LCT) and US (OTCQB:LVCLY) stock exchanges. The Company is incorporated in Australia, with its operations based in Australia and New Zealand.

For more information, visit [www.lctglobal.com](http://www.lctglobal.com) or follow @lctglobal on Twitter, Facebook or LinkedIn.

## **Forward-looking statements**

This document may contain certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.